Treatment of lung cancer using immune checkpoint inhibitors.
The treatment strategy of lung cancer is now significantly changing by the appearance of immune checkpoint inhibitors. Although anti-programmed cell death-1 (PD-1) antibody agents, nivolumab and pembrolizumab, have been already adopted as standard treatments in second line treatment of non-small-cell lung cancer, optimal use is essential due to the high costs and serious adverse effects. Therefore, further investigation of predictive markers in immune checkpoint blockade is ongoing, but robust one has not yet been identified. On the other hand, many clinical trials are now in progress regarding other immune checkpoint in- hibitors, combination therapy with cytotoxic or molecular target agents, different treatment settings and so on.